Twentyeight-Seven counts down to $65m series A

Sep 10, 2018 • Thierry Heles

Novartis Venture Fund, a founding investor, co-led a $65m series A round to launch cancer treatment developer Twentyeight-Seven Therapeutics.

US-based cancer-focused biotechnology developer Twentyeight-Seven Therapeutics (28-7) launched on Thursday with $65m in series A funding co-led by Novartis Venture Fund, the corporate venturing arm of pharmaceutical firm Novartis.

Investment firm MPM Capital co-led the round, which also featured Johnson & Johnson Innovation – JJDC and Astellas Venture Management, the respective corporate venture capital units of healthcare group Johnson & Johnson and pharmaceutical firm Astellas Pharma.

Vertex Ventures HC, a venture capital fund of Singaporean state-owned VC firm Vertex Ventures,…

LEADERSHIP SOCIETY

Informing, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.

Find out more

FUNDING ROUND DATA

Which corporates are backing which startups? Search our corporate deal database.

CVC DIRECTORY

Find details about global CVC units in the CVC Directory

NOMINATE

Make a nomination for Rising Stars and Emerging Leaders

Events

GCV Institute: CVC Investment Programs

Dec 3 -
Dec 4, 2024
Online

Find out more All events

Events

GCV Connect: Korea 2024

Dec 10 -
Dec 12, 2024
Seoul (South Korea)

Find out more All events

Events

GCV Institute: CVC Investment Programs

Jan 28 -
Jan 29, 2025
Online

Find out more All events

Events

GCV Institute: CVC Investment Programs

Mar 17 -
Mar 18, 2025
Palo Alto, CA (USA)

Find out more All events

Events

GCVI Summit 2025

Mar 18 -
Mar 20, 2025
Monterey, CA (USA)

Find out more All events

Events

GCV Institute: Landing the Value of Corporate Venturing

May 1 -
May 6, 2025
Online

Find out more All events

Events

GCV Symposium 2025

Jun 17 -
Jun 19, 2025
London (UK)

Find out more All events

About us

GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.